Latest News

Management of Tinea Capitis in Children Varies, Survey Finds


 

TOPLINE:

Tinea capitis management varies among US-based pediatric dermatologists, a national survey found.

METHODOLOGY:

  • The fungal scalp infection tinea capitis affects an estimated 3%-13% of children.
  • While international guidelines exist for the treatment of tinea capitis in infants and children, no such document has been developed in the United States.
  • Researchers distributed a survey by email to dermatologists through the and the Society for Pediatric Dermatology in the United States, asking about how they treated and managed pediatric patients with tinea capitis; 56 dermatologists participated.

TAKEAWAY:

  • Most respondents (88.2%) said they felt comfortable prescribing oral medications prior to confirmation for those aged 2-18 years ( was the most common choice in 60.4% of cases), compared with 81.6% for those aged 2 months to 2 years ( was the most common treatment choice in 41.5% of cases), and 48.7% for those aged 0-2 months ( was the most common choice in 28.6% of cases).
  • When asked what topical medication they would start prior to confirmation, most respondents said shampoo (62.3% for those aged 0-2 months and 75.5% each for those aged 2 months to 2 years and those aged 2-18 years), yet between 11.3% and 13% said they would use none.
  • The most common form of confirmatory testing was , followed by potassium hydroxide preparation, trichoscopy, and Wood’s lamp.
  • More than half of survey respondents would alter their choice of oral medication based on culture results, but most would not change their topical medication preference.

IN PRACTICE:

“The management of tinea capitis in the United States is currently variable, particularly with the introduction of newer antifungals,” the authors wrote. “Future steps involve establishing evidence-based clinical practice guidelines that consider drug efficacy, safety profiles, and costs.”

SOURCE:

Bernard Cohen, MD, of the Departments of Pediatrics and Dermatology at Johns Hopkins University, Baltimore, Maryland, led the research, which was published in Pediatric Dermatology.

LIMITATIONS:

Lower response rates associated with online surveys and predefined age groups restrict the granularity of responses.

DISCLOSURES:

The authors reported having no financial disclosures.

A version of this article appeared on Medscape.com.

Recommended Reading

Efficacy of Topical Clascoterone for Acne Increased Over Time, Analysis Shows
MDedge Dermatology
Novel Clinic Resulted in ‘Impressive’ Outcomes for Patients With Moderate to Severe Eczema
MDedge Dermatology
A Look at the Evidence Linking Diet to Skin Conditions
MDedge Dermatology
Hair Loss in Children: How to Spot and Treat Different Causes
MDedge Dermatology
Treating Acne Scars Can Improve Aesthetics, Quality of Life
MDedge Dermatology
Review Finds No Short-term MACE, VTE risk with JAK Inhibitors For Dermatoses
MDedge Dermatology
AAD Updates Guidelines for Managing Acne
MDedge Dermatology
Expert Shares Tips for Diagnosing, Managing Spitz Nevi
MDedge Dermatology
Dupilumab Improves AD Affecting the Hands, Feet
MDedge Dermatology
Study: Lifetime Cost of Vyjuvek Gene Therapy for DEB Could Be $15-$22 Million
MDedge Dermatology